Published On: Fri, Feb 10th, 2017

US Stem Cell Inc (OTCMKTS:USRM) Updates On Newest Publication By Its Chief Scientific Officer

US Stem Cell Inc (OTCMKTS:USRM) a Florida firm and pioneer in novel regenerative medicine offerings and physician-based stem cell treatments to animal and human patients, reported newest publication by CSO, Mr. Kristin Comella.

The details

Outcomes of the intradiscal implantation of platelet rich plasma plus stromal vascular fraction in subjects with degenerative disc disease was issued in the January publication of the Journal of Translational Medicine. The report focused on the implantation of SVF in subjects with degenerative disc disease.

Subjects undertook a local tumescent liposuction process to remove around 60 ml of fat matter from the abdomen. This was separated to separate the SVF and the cells were supplied directly into the injured discs. Subjects were observed for a 6 months’ period post-treatment, recording considerable decline in pain and growths in flexion.

Ms. Comella’s previous paper was published in the Journal of Translational Medicine edition of June. Using the same process, chronic ischemic cardiomyopathy subjects were assessed after SVF injection and capable to walk over 80 additional meters 3 months to 6 months following treatment.

At U.S. Stem they are dedicated to new technological therapies and advancements that provide a renewed sense of anticipation to subjects with degenerative diseases. The latest therapy, SVF is in a long-line of positive treatments they have pioneered. Comella intends to continue her SVF planned work, which has constantly repeated its robust safety profile and achievement in treating subjects.

US Stem cell is an emerging firm in the cellular therapy/ regenerative medicine industry. They are focused on the development, commercialization and discovery of cell based treatments that prevent, cure or treat disease by replacing and repairing aged or damaged tissue, organs and cells and restoring their usual function.

They consider that cellular therapeutics/ regenerative medicine will play a major role in positively transforming the natural history of diseases, eventually, they contend, reducing patient burdens, and reducing the related economic impact disease forces upon modern society.

© Copyright 2016 OTC News Magazine. All rights reserved.